Immunocore Holdings IMCR
NASDAQ IMCR
$36.13 -1.44 (-3.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunocore Holdings (IMCR) Cash from Investing Activities (2021 - 2026)

Immunocore Holdings (IMCR) posted Cash from Investing Activities of $4.2 million for Q1 2026, up 579.43% sequentially from -$880000.0 in Q4 2025, and down 56.51% YoY from $9.7 million in Q1 2025.

Analysis

Immunocore Holdings (IMCR) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Immunocore Holdings has reported Cash from Investing Activities for 6 years, with the latest figure at $4.2 million in Q1 2026.

  • Quarterly Cash from Investing Activities fell 56.51% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.8 million (up 93.67% YoY) and the FY2025 annual result came in at -$16.3 million, up 95.4% from the prior year.
  • Cash from Investing Activities climbed to $4.2 million in Q1 2026 per IMCR's latest filing, from -$880000.0 in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $9.7 million in Q1 2025 and troughed at -$350.3 million in Q2 2024.
  • A 5-year average of -$24.8 million and a median of -$817000.0 in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 25013.33% in 2024, then soared 2356.28% in 2025.
  • Over 5 years, Cash from Investing Activities stood at $389412.2 in 2022, then plunged by 309.8% to -$817000.0 in 2023, then sank by 333.29% to -$3.5 million in 2024, then surged by 75.14% to -$880000.0 in 2025, then surged by 579.43% to $4.2 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered $4.2 million, -$880000.0, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Immunocore Holdings 1.85 Bn 965.54 Mn 114.84 Mn -786,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -786,000.00
Mar 31, 2026 4.22 Mn
Dec 31, 2025 -880,000.00
Sep 30, 2025 5.25 Mn
Jun 30, 2025 -30.41 Mn
Mar 31, 2025 9.70 Mn
Dec 31, 2024 -3.54 Mn
Sep 30, 2024 -828,000.00
Jun 30, 2024 -350.33 Mn
Mar 31, 2024 -430,000.00
Dec 31, 2023 -817,000.00
Sep 30, 2023 -212,000.00
Jun 30, 2023 -1.40 Mn
Mar 31, 2023 -3.00 Mn
Dec 31, 2022 389,412.20
Sep 30, 2022 239,245.30
Dec 31, 2021 -357,222.81